These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1747438)

  • 1. Pretreatment EEG predicts short-term response to haloperidol treatment.
    Czobor P; Volavka J
    Biol Psychiatry; 1991 Nov; 30(9):927-42. PubMed ID: 1747438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve.
    Czobor P; Volavka J
    Psychiatry Res; 1992 May; 42(2):129-44. PubMed ID: 1631250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
    Czobor P; Volavka J
    J Clin Psychopharmacol; 1993 Oct; 13(5):332-42. PubMed ID: 7693770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment.
    Czobor P; Volavka J
    Compr Psychiatry; 1996; 37(3):205-15. PubMed ID: 8732588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early response to haloperidol treatment in chronic schizophrenia.
    Stern RG; Kahn RS; Harvey PD; Amin F; Apter SH; Hirschowitz J
    Schizophr Res; 1993 Aug; 10(2):165-71. PubMed ID: 8398949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
    Abuzzahab FS; Zimmerman RL
    J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment.
    Galderisi S; Mucci A; Di Gregorio MR; Bucci P; Maj M; Kemali D
    Eur Neuropsychopharmacol; 1990 Nov; 1(1):51-4. PubMed ID: 2136214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes.
    Arango C; Breier A; McMahon R; Carpenter WT; Buchanan RW
    Am J Psychiatry; 2003 Aug; 160(8):1421-7. PubMed ID: 12900303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
    Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
    Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol-induced changes in blink rates correlate with changes in BPRS score.
    Karson CN; Bigelow LB; Kleinman JE; Weinberger DR; Wyatt RJ
    Br J Psychiatry; 1982 May; 140():503-7. PubMed ID: 7104533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison.
    Kane JM; Marder SR; Schooler NR; Wirshing WC; Umbricht D; Baker RW; Wirshing DA; Safferman A; Ganguli R; McMeniman M; Borenstein M
    Arch Gen Psychiatry; 2001 Oct; 58(10):965-72. PubMed ID: 11576036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of determination of plasma haloperidol levels.
    Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol.
    Saletu B; Küfferle B; Anderer P; Grünberger J; Steinberger K
    Eur Neuropsychopharmacol; 1990 Nov; 1(1):27-36. PubMed ID: 1983779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of haloperidol concentrations to therapeutic response.
    Perry PJ; Pfohl BM; Kelly MW
    J Clin Psychopharmacol; 1988 Feb; 8(1):38-43. PubMed ID: 3350997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Wu GY
    Psychopharmacology (Berl); 2006 Sep; 188(1):12-7. PubMed ID: 16906395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.